Guardant Health will provide up to 100 free Shield blood tests per organization to support colorectal cancer screening events and outreach during Colorectal Cancer Awareness Month in March.
A study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.
Proscia and Owkin announced a partnership to integrate AI-driven MSI screening technology, expanding access to colorectal cancer diagnostics.
Universal DX initiated a clinical trial for its colorectal cancer screening blood test with the goal of achieving FDA premarket approval.
Read More
A new AI-based test assesses CD3 immune cells in early-stage bowel cancer tumors to predict recurrence risk.
Read More
Researchers have identified geographic “hot spots” in the U.S. with low colorectal cancer screening rates among Hispanic/Latino communities.
Read More
A new study reveals that an at-home colorectal cancer screening test, FIT, can reduce the risk of colorectal cancer death by 33%.
Read More
Mainz Biomed has applied for FDA Breakthrough Device Designation for its advanced non-invasive colorectal cancer screening test.
Read More
The new collaboration aims to enhance colorectal cancer (CRC) screening using advanced diagnostic platforms and novel biomarkers.
Read More
Mainz Biomed unveiled findings of the eAArly DETECT study that demonstrated high sensitivity and specificity of their colorectal cancer test.
Read More
The FDA’s Medical Devices Advisory Committee recommended approval of Guardant Health’s Shield blood test for colorectal cancer screening.
Read More
A new study found that 7.4% of patients repeated fecal testing rather than proceeding directly to colonoscopy as guidelines recommend.
Read More
Offering a choice between colonoscopy and a take-home screening kit more than doubled colorectal cancer screening rates.
Read More
Mainz Biomed N.V. announced results from a clinical study to evaluating integrating its portfolio into its colorectal cancer screening tool.
Read More
Mainz Biomed will present the findings of a study that evaluated its multimodal screening test for the detection of colorectal cancer.
Read More
Geneoscopy received U.S. FDA approval for ColoSense, a noninvasive colorectal cancer screening test that uses RNA biomarkers.
Read More
A significant gap exists in ensuring timely follow-up with colonoscopy after a positive stool test, hindering the effectiveness of screening.
Read More
New studies are cautioning against the use of blood tests to replace established colorectal cancer screening tests.
Read More